Friday, May 17, 2019
Home »
» Medical News Today: MiraLAX (Polyethylene glycol 3350)
Medical News Today: MiraLAX (Polyethylene glycol 3350)
MiraLAX is a brand-name, over-the-counter product that’s typically used to treat short-term constipation. It contains polyethylene glycol 3350, which also comes as store-branded generic products. MiraLAX comes as a powder that you mix with liquid to drink. Learn about side effects, warnings, dosage, and more.
Related Posts:
New cases of coronavirus keep falling, but hospitals stay busy Table by state Cabinet for Health and Family Services, adapted by Kentucky Health News By Al Cross Kentucky Health News Fewer people are getting the coronavirus in Kentucky, and the state's hospitals have fewer Cov… Read More
Kentucky's coronavirus positive-test rate inches up again; infection rate is about the same; 7-day new-case average falls Kentucky Dept. for Public Health map, adapted by Kentucky Health News; to enlarge, click on it. By Melissa Patrick Kentucky Health News Kentucky's coronavirus infection rate remains on a rough plateau, still to… Read More
Vaccines for children ages 5 to 11 are approved, but many parents appear reluctant; here are questions and answers Associated Press photo, provided by Pfizer By Melissa PatrickKentucky Health News The Centers for Disease Control and Prevention approved emergency use authorization of the Pfizer-BioNTech Covid-19 vaccine for 5- to… Read More
'Orange is still a bad color,' Beshear says, urging schools to keep mask mandates until students can get fully vaccinated Ky. Dept. for Public Health map, adapted by Ky. Health News; for a larger version, click on it. By Melissa Patrick Kentucky Health News Gov. Andy Beshear and his public-health chief are urging Kentuckians to get va… Read More
Coronavirus numbers continue on a rough plateau Kentucky Health News graph, from state data By Melissa PatrickKentucky Health News With Wednesday's coronavirus metrics about the same as Tuesday's, the pandemic in Kentucky remains on a rough plateau. The state repo… Read More
0 comments:
Post a Comment